Interesting... surprised not to see Telix on the list of...

Interesting... surprised not to see Telix on the list of partners/presenters?

https://www.dfhcc.harvard.edu/events/detail/event/targeted-radiopharmaceutical-summit-us/

The brand-new Targeted Radiopharmaceuticals Summit US (TRP US) is the only industry-led meeting dedicated to the development of next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months, with a wave of new investment in light of Lutathera’s extraordinary performance.

Are you part of a pharmaceutical business aiming to have their Theranostic approved? If so, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging.

Hear the latest insights, case studies, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies.

https://targeted-radiopharma-us.com/

Welcome to the Inaugural Targeted Radiopharmaceuticals Summit US

With two prostate cancer-focused approvals in the last year, RLT is finally getting the attention it deserves from investors, biotech, and the wider oncology field. Though still the 3rd line of exotic therapy, the ever-growing pipeline of therapeutics is set to deliver new life-saving therapeutics to patients with various unmet oncological needs.

To aid this tidal wave of investment comes the brand new Targeted Radiopharmaceuticals Summit US (TRP US), the only industry-led gathering dedicated to the development of next-generation radioligands.

Do you work for a pharmaceutical company that wants to have its Theranostic approved? If so, this summit is designed to provide you with a comprehensive grasp of the fast-paced radiopharmaceutical industry while simultaneously teaching you about the vital role of diagnostic imaging.

Hear the latest insights, case studies, and novel data to accelerate the development of next-generation radioligand medicines from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies.

This summit will strive to tackle topics that are on every drug developer's mind:

• How do we identify and validate new targets?
• Can we combine targeted radiopharmaceuticals with immunotherapy or other targeted oncology methods?
• How do we improve current clinical design methodologies and patient selection strategies?
• Where can improvements be made to the current supply and fulfillment models?

https://targeted-radiopharma-us.com/whats-on/speakers/